Related Experiment Videos

Smad2 and Smad4 gene mutations in hepatocellular carcinoma

M C Yakicier1, M B Irmak, A Romano

  • 1Department of Molecular Biology and Genetics, Bilkent University 06533 Bilkent, Ankara, Turkey.

Oncogene
|September 22, 1999
PubMed

Insights

Transforming growth factor-beta (TGF-beta) pathway alterations, including Smad2 and Smad4 gene mutations, are observed in hepatocellular carcinoma (HCC). These mutations suggest oxidative stress involvement in liver cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hepatology

Background:

  • Transforming growth factor-beta (TGF-beta) acts as a negative regulator of liver growth.
  • The Smad gene family mediates the TGF-beta pathway and are potential tumor suppressors in hepatocellular carcinoma (HCC).

Purpose of the Study:

  • To investigate mutations in Smad2 and Smad4 genes within HCC tissues.
  • To explore the role of the TGF-beta pathway in the development of HCC.

Main Methods:

  • Analysis of 35 HCC and adjacent non-tumour liver tissues.
  • Sequencing of Smad2 and Smad4 genes to identify mutations.

Main Results:

  • Somatic mutations were identified in three tumors: two in Smad4 (Asp332Gly, Cys401Arg) and one in Smad2 (Gln407Arg).
  • All detected mutations were A:T --> G:C transitions, indicative of oxidative stress, potentially linked to mitochondrial DNA damage.

Conclusions:

  • The TGF-beta signaling pathway is demonstrably altered in hepatocellular carcinoma.
  • Oxidative stress may play a role in the pathogenesis of HCC through Smad gene mutations.

Related Concept Videos